Lead Product(s): Samarium Sm-153
Therapeutic Area: Pediatrics/Neonatology
Highest Development Status: Undisclosed Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 22, 2020
Q2Earth has signed an Exclusive Dealing Option Agreement with IGL Pharma to potentially execute a worldwide, exclusive license agreement for the radiopharmaceutical Samarium-153 DOTMP .